

ASX ANNOUNCEMENT**ADMEDUS SHIPS CARDIOCEL® TO US FROM NEW FACILITY**

- Admedus' new WA bio-manufacturing facility now manufacturing CardioCel®
- Initial shipment from new manufacturing facility
- Admedus' CardioCel® now in 9 US centres
- Official opening of WA bio-manufacturing facility Friday 15th of August

Brisbane, Australia, 14th of August, 2014

Admedus (ASX: AHZ) today announced that it has commenced shipments of CardioCel® to the US from its Western Australian manufacturing plant. Admedus acquired the state-of-the-art facility in January this year to scale up manufacturing of CardioCel® for supply to global markets.

"Our manufacturing team has done a remarkable job in getting production up and running in such a short time." said Admedus CEO Mr. Lee Rodne

"This is a significant milestone for the company and will culminate in the official opening of the facility on the 15th of August."

Admedus has seen a high level of initial interest for CardioCel® from the US market, having received its initial product order in June. At present, there are 9 centres using the product which includes some of the leading cardiovascular surgical units in the country.

"Our sales teams have been able to generate considerable interest for CardioCel® from surgeons globally, particularly with our strong pre-clinical data and successful patient outcomes to date. Bringing our facility into production is very exciting to us and allows us to continually expand our reach by bringing CardioCel® to our customers for the repair and reconstruction of cardiac defects, including the repair of heart valves" said Mr. Rodne.

The manufacturing facility also enables Admedus to undertake additional product development to expand the range of regenerative tissue products for both cardiovascular applications and for other surgical indications that require repair and reconstruction.

To date, CardioCel® has been used in a range of cardiovascular repair and reconstruction procedures in both adults and paediatrics, including hole-in-the-heart repairs and heart valve reconstructions. Recently, in the US, CardioCel® has been used in less-invasive robotic surgery to repair defective heart valves which is a major step forward for the use of CardioCel® in cardiovascular surgery.

Follow us on Twitter: @Admedus and on Facebook:
www.facebook.com/pages/Admedus.

For more information, please contact:

Dr. Julian Chick, Chief Operating Officer Admedus Limited Tel: +61 3 9620 5454

Media:

Kyahn Williamson

Buchan Consulting

+61 3 8866 4722

tweston@buchanwe.com.au

About Admedus Limited

Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential such as Herpes and Human Papillomavirus.

Further information on the Company can be found on www.admedus.com